Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis

par Crowley, J.J., Warren, R.B., Cather, J.C.
Publié dans J Eur Acad Dermatol Venereol (2019)

Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

par Wan, M. T., Alvarez, J., Shin, D. B., Dommasch, E. D., Wu, J. J., Gelfand, J. M.
Publié dans J Eur Acad Dermatol Venereol (2018)

Real‐life effectiveness of once‐daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52‐week PRO‐long study...

par Lambert, J., Hol, C.W., Vink, J.
Publié dans J Eur Acad Dermatol Venereol (2015)

COVID‐19 and its implications for Dermatology and Venereology

par Ring, J.
Publié dans J Eur Acad Dermatol Venereol (2020)

The skin in the era of coronavirus pandemic

par Ring, J.
Publié dans J Eur Acad Dermatol Venereol (2020)

Dermato‐venereology in the year of coronavirus – Hot topics in research and patient care

par Ring, J.
Publié dans J Eur Acad Dermatol Venereol (2021)

Impact of the COVID‐19 pandemic on inpatient dermatology: a multicentre study from Hubei, China

par Zhang, Y., Wen, J., Alamgir, M., Xie, J., Jing, H., Fang, M., Wang, J., Zhang, M., Meng, Z., Yang, L., Tao, J.
Publié dans J Eur Acad Dermatol Venereol (2020)

Autoantibodies in Covid‐19 – a model for viral induced autoimmunity

par Berger, J., Volc, S.
Publié dans J Eur Acad Dermatol Venereol (2021)

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice

par Kimball, A.B., Crowley, J.J., Papp, K., Calimlim, B., Duan, Y., Fleischer, A.B., Sobell, J.
Publié dans J Eur Acad Dermatol Venereol (2020)

Acro‐ischaemia and COVID‐19 infection: clinical and histopathological features

par Calvão, J., Relvas, M., Pinho, A., Brinca, A., Cardoso, J.C.
Publié dans J Eur Acad Dermatol Venereol (2020)

Penile ischaemia secondary to COVID‐19: why should the dermatologist be concerned?

par Sarkis, P., Sarkis, J., Alkassis, M., Assaf, J., El Gharib, K.
Publié dans J Eur Acad Dermatol Venereol (2021)

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from...

par Mease, P.J., Palmer, J.B., Hur, P., Strober, B.E., Lebwohl, M., Karki, C., Reed, G.W., Etzel, C.J., Greenberg, J.D., Helliwell, P. S.
Publié dans J Eur Acad Dermatol Venereol (2019)

Efficacy of hydrogel patches in preventing facial skin damage caused by mask compression in fighting against coronavirus disease 2019: a short‐term, self‐controlled study

par Dong, L., Yang, L., Li, Y., Yang, J., An, X., Yang, L., Zhou, N., Zhang, Y., Du, H., Lan, J., Song, Z., Miao, X., Zhu, J., Tao, J.
Publié dans J Eur Acad Dermatol Venereol (2020)

Measurement of Tanning Dependence

par Heckman, C.J., Darlow, S., Kloss, J.D., Cohen-Filipic, J., Manne, S.L., Munshi, T., Yaroch, A.L., Perlis, C.
Publié 2013

Incidence and prognosis of COVID‐19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study

par Georgakopoulos, J.R., Mufti, A., Vender, R., Prajapati, V.H., Yeung, J.
Publié dans J Eur Acad Dermatol Venereol (2021)

Occupational skin disease during the COVID‐19 pandemic, as captured in a Dermatology staff clinic in the United Kingdom

par Hadjieconomou, S., Hughes, J., Kamath, S.
Publié dans J Eur Acad Dermatol Venereol (2020)

Concerns and perceptions of patients with psoriatic disease during the COVID‐19 pandemic: results from a two‐wave survey by the National Psoriasis Foundation

par Gondo, G.C., Bell, S.J., Slayden, J., Ullmann, G., Blauvelt, A.
Publié dans J Eur Acad Dermatol Venereol (2021)

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis

par Merola, J.F., Ghislain, P.‐D., Dauendorffer, J.N., Potts Bleakman, A., Brnabic, A.J.M., Burge, R., Riedl, E.
Publié dans J Eur Acad Dermatol Venereol (2020)

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a...

par van Vugt, L.J., van den Reek, J.M.P.A., Meulewaeter, E., Hakobjan, M., Heddes, N., Traks, T., Kingo, K., Galluzzo, M., Talamonti, M., Lambert, J., Coenen, M.J.H., de Jong, E.M.G.J.
Publié dans J Eur Acad Dermatol Venereol (2019)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from t...

par Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., Piguet, V.
Publié dans J Eur Acad Dermatol Venereol (2018)